

Commission Implementing Regulation (EU) 2020/1187 of 7 August 2020 granting a Union authorisation for the biocidal product family ‘Iodine based products – CID LINES NV’ (Text with EEA relevance)

- Article 1 A Union authorisation with authorisation number EU-0022265-0000 is granted to...
- Article 2 This Regulation shall enter into force on the twentieth day...
Signature

ANNEX

Summary of product characteristics for a biocidal product family

Iodine based products – CID LINES NV
Product type 3 – Veterinary hygiene (Disinfectants)
Product type 4 – Food and feed area (Disinfectants)
Authorisation number: EU-0022265-0000
R4BP asset number: EU-0022265-0000

PART I

FIRST INFORMATION LEVEL

1. ADMINISTRATIVE INFORMATION
 - 1.1. Family name
 - 1.2. Product type(s)
 - 1.3. Authorisation holder
 - 1.4. Manufacturer(s) of the biocidal products
 - 1.5. Manufacturer(s) of the active substance(s)
2. PRODUCT FAMILY COMPOSITION AND FORMULATION
 - 2.1. Qualitative and quantitative information on the composition of the family...
 - 2.2. Type(s) of formulation

PART II

SECOND INFORMATION LEVEL – META SPC(S)

META SPC 1

1. META SPC 1 ADMINISTRATIVE INFORMATION
 - 1.1. Meta SPC 1 identifier
 - 1.2. Suffix to the authorisation number
 - 1.3. Product type(s)
2. META SPC 1 COMPOSITION
 - 2.1. Qualitative and quantitative information on the composition of the meta...
 - 2.2. Type(s) of formulation of the meta SPC 1
3. HAZARD AND PRECAUTIONARY STATEMENTS OF THE META SPC 1
4. AUTHORISED USE(S) OF THE META SPC 1

Changes to legislation: There are currently no known outstanding effects for the
Commission Implementing Regulation (EU) 2020/1187. (See end of Document for details)

- 4.1. Use description
 - 4.1.1. Use-specific instructions for use
 - 4.1.2. Use-specific risk mitigation measures
 - 4.1.3. Where specific to the use, the particulars of likely direct...
 - 4.1.4. Where specific to the use, the instructions for safe disposal...
 - 4.1.5. Where specific to the use, the conditions of storage and...
- 5. GENERAL DIRECTIONS FOR USE OF THE META SPC 1
 - 5.1. Instructions for use
 - 5.2. Risk mitigation measures
 - 5.3. Particulars of likely direct or indirect effects, first aid instructions...
 - 5.4. Instructions for safe disposal of the product and its packaging...
 - 5.5. Conditions of storage and shelf-life of the product under normal...
- 6. OTHER INFORMATION
- 7. THIRD INFORMATION LEVEL: INDIVIDUAL PRODUCTS IN THE META SPC 1...
 - 7.1. Trade name(s), authorisation number and specific composition of each individual...

META SPC 2

- 1. META SPC 2 ADMINISTRATIVE INFORMATION
 - 1.1. Meta SPC 2 identifier
 - 1.2. Suffix to the authorisation number
 - 1.3. Product type(s)
- 2. META SPC 2 COMPOSITION
 - 2.1. Qualitative and quantitative information on the composition of the meta...
 - 2.2. Type(s) of formulation of the meta SPC 2
- 3. HAZARD AND PRECAUTIONARY STATEMENTS OF THE META SPC 2
- 4. AUTHORISED USE(S) OF THE META SPC 2
 - 4.1. Use description
 - 4.1.1. Use-specific instructions for use
 - 4.1.2. Use-specific risk mitigation measures
 - 4.1.3. Where specific to the use, the particulars of likely direct...
 - 4.1.4. Where specific to the use, the instructions for safe disposal...
 - 4.1.5. Where specific to the use, the conditions of storage and...
- 5. GENERAL DIRECTIONS FOR USE OF THE META SPC 2
 - 5.1. Instructions for use
 - 5.2. Risk mitigation measures
 - 5.3. Particulars of likely direct or indirect effects, first aid instructions...
 - 5.4. Instructions for safe disposal of the product and its packaging...
 - 5.5. Conditions of storage and shelf-life of the product under normal...
- 6. OTHER INFORMATION
- 7. THIRD INFORMATION LEVEL: INDIVIDUAL PRODUCTS IN THE META SPC 2...
 - 7.1. Trade name(s), authorisation number and specific composition of each individual...
 - 7.2. Trade name(s), authorisation number and specific composition of each individual...

META SPC 3

- 1. META SPC 3 ADMINISTRATIVE INFORMATION
 - 1.1. Meta SPC 3 identifier
 - 1.2. Suffix to the authorisation number

- 1.3. Product type(s)
2. META SPC 3 COMPOSITION
 - 2.1. Qualitative and quantitative information on the composition of the meta...
 - 2.2. Type(s) of formulation of the meta SPC 3
3. HAZARD AND PRECAUTIONARY STATEMENTS OF THE META SPC 3
4. AUTHORISED USE(S) OF THE META SPC 3
 - 4.1. Use description
 - 4.1.1. Use-specific instructions for use
 - 4.1.2. Use-specific risk mitigation measures
 - 4.1.3. Where specific to the use, the particulars of likely direct...
 - 4.1.4. Where specific to the use, the instructions for safe disposal...
 - 4.1.5. Where specific to the use, the conditions of storage and...
5. GENERAL DIRECTIONS FOR USE OF THE META SPC 3
 - 5.1. Instructions for use
 - For disinfection of the skin:
 - 5.2. Risk mitigation measures
 - 5.3. Particulars of likely direct or indirect effects, first aid instructions...
 - 5.4. Instructions for safe disposal of the product and its packaging...
 - 5.5. Conditions of storage and shelf-life of the product under normal...
6. OTHER INFORMATION
7. THIRD INFORMATION LEVEL: INDIVIDUAL PRODUCTS IN THE META SPC 3...
 - 7.1. Trade name(s), authorisation number and specific composition of each individual...
 - 7.2. Trade name(s), authorisation number and specific composition of each individual...

META SPC 4

1. META SPC 4 ADMINISTRATIVE INFORMATION
 - 1.1. Meta SPC 4 identifier
 - 1.2. Suffix to the authorisation number
 - 1.3. Product type(s)
2. META SPC 4 COMPOSITION
 - 2.1. Qualitative and quantitative information on the composition of the meta...
 - 2.2. Type(s) of formulation of the meta SPC 4
3. HAZARD AND PRECAUTIONARY STATEMENTS OF THE META SPC 4
4. AUTHORISED USE(S) OF THE META SPC 4
 - 4.1. Use description
 - 4.1.1. Use-specific instructions for use
 - For disinfection of the teats:
 - 4.1.2. Use-specific risk mitigation measures
 - 4.1.3. Where specific to the use, the particulars of likely direct...
 - 4.1.4. Where specific to the use, the instructions for safe disposal...
 - 4.1.5. Where specific to the use, the conditions of storage and...
 - 4.2. Use description
 - 4.2.1. Use-specific instructions for use
 - For disinfection of the skin:
 - 4.2.2. Use-specific risk mitigation measures
 - 4.2.3. Where specific to the use, the particulars of likely direct...
 - 4.2.4. Where specific to the use, the instructions for safe disposal...
 - 4.2.5. Where specific to the use, the conditions of storage and...

Changes to legislation: There are currently no known outstanding effects for the
Commission Implementing Regulation (EU) 2020/1187. (See end of Document for details)

5. GENERAL DIRECTIONS FOR USE OF THE META SPC 4
 - 5.1. Instructions for use
 - 5.2. Risk mitigation measures
 - 5.3. Particulars of likely direct or indirect effects, first aid instructions...
 - 5.4. Instructions for safe disposal of the product and its packaging...
 - 5.5. Conditions of storage and shelf-life of the product under normal...
6. OTHER INFORMATION
7. THIRD INFORMATION LEVEL: INDIVIDUAL PRODUCTS IN THE META SPC 4...
 - 7.1. Trade name(s), authorisation number and specific composition of each individual...

META SPC 5

1. META SPC 5 ADMINISTRATIVE INFORMATION
 - 1.1. Meta SPC 5 identifier
 - 1.2. Suffix to the authorisation number
 - 1.3. Product type(s)
2. META SPC 5 COMPOSITION
 - 2.1. Qualitative and quantitative information on the composition of the meta...
 - 2.2. Type(s) of formulation of the meta SPC 5
3. HAZARD AND PRECAUTIONARY STATEMENTS OF THE META SPC 5
4. AUTHORISED USE(S) OF THE META SPC 5
 - 4.1. Use description
 - 4.1.1. Use-specific instructions for use
 - 4.1.2. Use-specific risk mitigation measures
 - 4.1.3. Where specific to the use, the particulars of likely direct...
 - 4.1.4. Where specific to the use, the instructions for safe disposal...
 - 4.1.5. Where specific to the use, the conditions of storage and...
5. GENERAL DIRECTIONS FOR USE OF THE META SPC 5
 - 5.1. Instructions for use
 - 5.2. Risk mitigation measures
 - 5.3. Particulars of likely direct or indirect effects, first aid instructions...
 - 5.4. Instructions for safe disposal of the product and its packaging...
 - 5.5. Conditions of storage and shelf-life of the product under normal...
6. OTHER INFORMATION
7. THIRD INFORMATION LEVEL: INDIVIDUAL PRODUCTS IN THE META SPC 5...
 - 7.1. Trade name(s), authorisation number and specific composition of each individual...
 - 7.2. Trade name(s), authorisation number and specific composition of each individual...

META SPC 6

1. META SPC 6 ADMINISTRATIVE INFORMATION
 - 1.1. Meta SPC 6 identifier
 - 1.2. Suffix to the authorisation number
 - 1.3. Product type(s)
2. META SPC 6 COMPOSITION
 - 2.1. Qualitative and quantitative information on the composition of the meta...
 - 2.2. Type(s) of formulation of the meta SPC 6
3. HAZARD AND PRECAUTIONARY STATEMENTS OF THE META SPC 6

4. AUTHORISED USE(S) OF THE META SPC 6
 - 4.1. Use description
 - 4.1.1. Use-specific instructions for use
 - 4.1.2. Use-specific risk mitigation measures
 - 4.1.3. Where specific to the use, the particulars of likely direct...
 - 4.1.4. Where specific to the use, the instructions for safe disposal...
 - 4.1.5. Where specific to the use, the conditions of storage and...
5. GENERAL DIRECTIONS FOR USE OF THE META SPC 6
 - 5.1. Instructions for use
 - 5.2. Risk mitigation measures
 - 5.3. Particulars of likely direct or indirect effects, first aid instructions...
 - 5.4. Instructions for safe disposal of the product and its packaging...
 - 5.5. Conditions of storage and shelf-life of the product under normal...
6. OTHER INFORMATION
7. THIRD INFORMATION LEVEL: INDIVIDUAL PRODUCTS IN THE META SPC 6...
 - 7.1. Trade name(s), authorisation number and specific composition of each individual...

META SPC 7

1. META SPC 7 ADMINISTRATIVE INFORMATION
 - 1.1. Meta SPC 7 identifier
 - 1.2. Suffix to the authorisation number
 - 1.3. Product type(s)
2. META SPC 7 COMPOSITION
 - 2.1. Qualitative and quantitative information on the composition of the meta...
 - 2.2. Type(s) of formulation of the meta SPC 7
3. HAZARD AND PRECAUTIONARY STATEMENTS OF THE META SPC 7
4. AUTHORISED USE(S) OF THE META SPC 7
 - 4.1. Use description
 - 4.1.1. Use-specific instructions for use
 - 4.1.2. Use-specific risk mitigation measures
 - 4.1.3. Where specific to the use, the particulars of likely direct...
 - 4.1.4. Where specific to the use, the instructions for safe disposal...
 - 4.1.5. Where specific to the use, the conditions of storage and...
 - 4.2. Use description
 - 4.2.1. Use-specific instructions for use
 - 4.2.2. Use-specific risk mitigation measures
 - 4.2.3. Where specific to the use, the particulars of likely direct...
 - 4.2.4. Where specific to the use, the instructions for safe disposal...
 - 4.2.5. Where specific to the use, the conditions of storage and...
5. GENERAL DIRECTIONS FOR USE OF THE META SPC 7
 - 5.1. Instructions for use
 - 5.2. Risk mitigation measures
 - 5.3. Particulars of likely direct or indirect effects, first aid instructions...
 - 5.4. Instructions for safe disposal of the product and its packaging...
 - 5.5. Conditions of storage and shelf-life of the product under normal...
6. OTHER INFORMATION
7. THIRD INFORMATION LEVEL: INDIVIDUAL PRODUCTS IN THE META SPC 7...
 - 7.1. Trade name(s), authorisation number and specific composition of each individual...

META SPC 8

1. **META SPC 8 ADMINISTRATIVE INFORMATION**
 - 1.1. Meta SPC 8 identifier
 - 1.2. Suffix to the authorisation number
 - 1.3. Product type(s)
2. **META SPC 8 COMPOSITION**
 - 2.1. Qualitative and quantitative information on the composition of the meta...
 - 2.2. Type(s) of formulation of the meta SPC 8
3. **HAZARD AND PRECAUTIONARY STATEMENTS OF THE META SPC 8**
4. **AUTHORISED USE(S) OF THE META SPC 8**
 - 4.1. Use description
 - 4.1.1. Use-specific instructions for use
 - 4.1.2. Use-specific risk mitigation measures
 - 4.1.3. Where specific to the use, the particulars of likely direct...
 - 4.1.4. Where specific to the use, the instructions for safe disposal...
 - 4.1.5. Where specific to the use, the conditions of storage and...
 - 4.2. Use description
 - 4.2.1. Use-specific instructions for use
 - 4.2.2. Use-specific risk mitigation measures
 - 4.2.3. Where specific to the use, the particulars of likely direct...
 - 4.2.4. Where specific to the use, the instructions for safe disposal...
 - 4.2.5. Where specific to the use, the conditions of storage and...
5. **GENERAL DIRECTIONS FOR USE OF THE META SPC 8**
 - 5.1. Instructions for use
 - 5.2. Risk mitigation measures
 - 5.3. Particulars of likely direct or indirect effects, first aid instructions...
 - 5.4. Instructions for safe disposal of the product and its packaging...
 - 5.5. Conditions of storage and shelf-life of the product under normal...
6. **OTHER INFORMATION**
7. **THIRD INFORMATION LEVEL: INDIVIDUAL PRODUCTS IN THE META SPC 8...**
 - 7.1. Trade name(s), authorisation number and specific composition of each individual...

META SPC 9

1. **META SPC 9 ADMINISTRATIVE INFORMATION**
 - 1.1. Meta SPC 9 identifier
 - 1.2. Suffix to the authorisation number
 - 1.3. Product type(s)
2. **META SPC 9 COMPOSITION**
 - 2.1. Qualitative and quantitative information on the composition of the meta...
 - 2.2. Type(s) of formulation of the meta SPC 9
3. **HAZARD AND PRECAUTIONARY STATEMENTS OF THE META SPC 9**
4. **AUTHORISED USE(S) OF THE META SPC 9**
 - 4.1. Use description
 - 4.1.1. Use-specific instructions for use
 - 4.1.2. Use-specific risk mitigation measures
 - 4.1.3. Where specific to the use, the particulars of likely direct...
 - 4.1.4. Where specific to the use, the instructions for safe disposal...
 - 4.1.5. Where specific to the use, the conditions of storage and...
5. **GENERAL DIRECTIONS FOR USE OF THE META SPC 9**

- 5.1. Instructions for use
- 5.2. Risk mitigation measures
- 5.3. Particulars of likely direct or indirect effects, first aid instructions...
- 5.4. Instructions for safe disposal of the product and its packaging...
- 5.5. Conditions of storage and shelf-life of the product under normal...
- 6. OTHER INFORMATION
- 7. THIRD INFORMATION LEVEL: INDIVIDUAL PRODUCTS IN THE META SPC 9...
- 7.1. Trade name(s), authorisation number and specific composition of each individual...

META SPC 10

- 1. META SPC 10 ADMINISTRATIVE INFORMATION
 - 1.1. Meta SPC 10 identifier
 - 1.2. Suffix to the authorisation number
 - 1.3. Product type(s)
- 2. META SPC 10 COMPOSITION
 - 2.1. Qualitative and quantitative information on the composition of the meta...
 - 2.2. Type(s) of formulation of the meta SPC 10
- 3. HAZARD AND PRECAUTIONARY STATEMENTS OF THE META SPC 10
- 4. AUTHORISED USE(S) OF THE META SPC 10
 - 4.1. Use description
 - 4.1.1. Use-specific instructions for use
 - 4.1.2. Use-specific risk mitigation measures
 - 4.1.3. Where specific to the use, the particulars of likely direct...
 - 4.1.4. Where specific to the use, the instructions for safe disposal...
 - 4.1.5. Where specific to the use, the conditions of storage and...
- 5. GENERAL DIRECTIONS FOR USE OF THE META SPC 10
 - 5.1. Instructions for use
 - 5.2. Risk mitigation measures
 - 5.3. Particulars of likely direct or indirect effects, first aid instructions...
 - 5.4. Instructions for safe disposal of the product and its packaging...
 - 5.5. Conditions of storage and shelf-life of the product under normal...
- 6. OTHER INFORMATION
- 7. THIRD INFORMATION LEVEL: INDIVIDUAL PRODUCTS IN THE META SPC 10...
- 7.1. Trade name(s), authorisation number and specific composition of each individual...

META SPC 11

- 1. META SPC 11 ADMINISTRATIVE INFORMATION
 - 1.1. Meta SPC 11 identifier
 - 1.2. Suffix to the authorisation number
 - 1.3. Product type(s)
- 2. META SPC 11 COMPOSITION
 - 2.1. Qualitative and quantitative information on the composition of the meta...
 - 2.2. Type(s) of formulation of the meta SPC 11
- 3. HAZARD AND PRECAUTIONARY STATEMENTS OF THE META SPC 11
- 4. AUTHORISED USE(S) OF THE META SPC 11
 - 4.1. Use description
 - 4.1.1. Use-specific instructions for use

Changes to legislation: There are currently no known outstanding effects for the
Commission Implementing Regulation (EU) 2020/1187. (See end of Document for details)

- 4.1.2. Use-specific risk mitigation measures
- 4.1.3. Where specific to the use, the particulars of likely direct...
- 4.1.4. Where specific to the use, the instructions for safe disposal...
- 4.1.5. Where specific to the use, the conditions of storage and...
- 5. GENERAL DIRECTIONS FOR USE OF THE META SPC 11
 - 5.1. Instructions for use
 - 5.2. Risk mitigation measures
 - 5.3. Particulars of likely direct or indirect effects, first aid instructions...
 - 5.4. Instructions for safe disposal of the product and its packaging...
 - 5.5. Conditions of storage and shelf-life of the product under normal...
- 6. OTHER INFORMATION
- 7. THIRD INFORMATION LEVEL: INDIVIDUAL PRODUCTS IN THE META SPC 11...
 - 7.1. Trade name(s), authorisation number and specific composition of each individual...

META SPC 12

- 1. META SPC 12 ADMINISTRATIVE INFORMATION
 - 1.1. Meta SPC 12 identifier
 - 1.2. Suffix to the authorisation number
 - 1.3. Product type(s)
- 2. META SPC 12 COMPOSITION
 - 2.1. Qualitative and quantitative information on the composition of the meta...
 - 2.2. Type(s) of formulation of the meta SPC 12
- 3. HAZARD AND PRECAUTIONARY STATEMENTS OF THE META SPC 12
- 4. AUTHORISED USE(S) OF THE META SPC 12
 - 4.1. Use description
 - 4.1.1. Use-specific instructions for use
 - 4.1.2. Use-specific risk mitigation measures
 - 4.1.3. Where specific to the use, the particulars of likely direct...
 - 4.1.4. Where specific to the use, the instructions for safe disposal...
 - 4.1.5. Where specific to the use, the conditions of storage and...
- 5. GENERAL DIRECTIONS FOR USE OF THE META SPC 12
 - 5.1. Instructions for use
 - 5.2. Risk mitigation measures
 - 5.3. Particulars of likely direct or indirect effects, first aid instructions...
 - 5.4. Instructions for safe disposal of the product and its packaging...
 - 5.5. Conditions of storage and shelf-life of the product under normal...
- 6. OTHER INFORMATION
- 7. THIRD INFORMATION LEVEL: INDIVIDUAL PRODUCTS IN THE META SPC 12...
 - 7.1. Trade name(s), authorisation number and specific composition of each individual...
 - 7.2. Trade name(s), authorisation number and specific composition of each individual...

Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Regulation (EU) 2020/1187. (See end of Document for details)

- (1) [OJ L 167, 27.6.2012, p. 1.](#)
- (2) Commission Delegated Regulation (EU) 2017/2100 of 4 September 2017 setting out scientific criteria for the determination of endocrine-disrupting properties pursuant to Regulation (EU) No 528/2012 of the European Parliament and Council ([OJ L 301, 17.11.2017, p. 1.](#)).
- (3) ECHA opinion of 11 December 2019 on the Union authorisation of ‘Iodine based products – CID LINES NV’ (ECHA/BPC/237/2019).

Changes to legislation:

There are currently no known outstanding effects for the Commission Implementing Regulation (EU) 2020/1187.